Identification of Core SASP-Related Genes TGFBI and ANXA6 for Diagnosing Ulcerative Colitis-Related Colorectal Cancer Through Machine Learning
Related Experiment Video
Updated: Jan 17, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
Jukun Zhang1, Ping Wang2, Siqi Yuan1
1Henan Medical Key Laboratory of Gastrointestinal Microecology and Hepatology, Department of Gastroenterology, the First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, 471000, Henan Province, People's Republic of China.
Purpose:
To explore the role of senescence-associated secretory phenotype (SASP) in ulcerative colitis-related colorectal cancer (UCRCC) precision diagnosis and pathogenesis.
Methods:
In this study, we first screened the SASP-related genes (SASPRGs) in the ulcerative colitis (UC) and colorectal cancer (CRC) datasets using differentially expressed genes (DEGs) and weighted gene co-expression network analysis (WGCNA). Subsequently, the core SASPRGs were further identified using 113 combinations of 10 machine learning algorithms, and evaluating their expression levels, diagnostic efficacy, prognostic value, and relationship with immune cells. Expression patterns of core SASPRGs were analyzed using scRNA-seq, and a molecular regulatory network was constructed. In addition, immunotherapy response and drug sensitivity analysis were conducted to screen therapeutic drugs targeting core SASPRGs. Finally, their expression levels were validated through in vivo experiments.
Results:
We identified 12 core SASPRGs, among which TGFBI and ANXA6 exhibited satisfactory diagnostic efficacy and prognostic value for UC and CRC. ANXA6 and TGFBI are highly expressed in monocytes and fibroblasts, and are associated with the infiltration of multiple immune cells. In addition, high TGFBI and ANXA6 groups showed poor responses to immunotherapy. The candidate therapeutic drugs screened by drug sensitivity analysis showed good binding ability with ANXA6 and TGFBI. Finally, the expression levels of TGFBI and ANXA6 were significantly increased in UC and CRC mouse models.
Conclusion:
Overall, TGFBI and ANXA6 are crucial in UCRCC, serving as novel diagnostic markers. They exhibit robust predictive capabilities on patient prognosis and immunotherapy response, offering actionable insights to optimize therapeutic decision-making and advance personalized treatment paradigms in UCRCC management.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
Related Concept Videos
TGF - β Signaling Pathway
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...